DrugMapper
Browse
Therapeutic Area
CANCER (51)
CARDIOVASCULAR (45)
DENTISTRY (2)
DERMATOLOGY (31)
DIABETES DRUGS & ENDOCRINOLOGY (61)
EMERGENCY MEDICINE (3)
ENT (5)
EYE (23)
GASTROINTESTINAL (29)
HEMATOLOGY (23)
MUSCULOSKELETAL (28)
NEUROLOGY DRUGS & NERVOUS SYSTEM (50)
PEDIATRICS (27)
PHARMACOLOGY (8)
PREGNANCY AND GYNECOLOGY (30)
RESPIRATORY (42)
RHEUMATOLOGY (19)
OTHER (1482)
Therapeutic Indication
Adverse Reaction (System Organ Classification)
Mechanism of Action
Primary Target
Target Level
Level 1
Level 2
Level 3
Level 4
Level 5
Level 6
Active Pharmaceutical Ingredients (APIs)
Small Molecules
ProDrugs
Antibodies
CNS drugs
Metabolites
Search
Therapeutic Indication
Adverse Reaction (System Organ Classification)
Mechanism of Action
Target Sequence
Chemical Structure
Physicochemical Properties
Analyze
Networks
Chemical Similarity
Scaffold Similarity
KNIME workflow
Downloads
Web services
Bulk Downloads
About
DrugMapper FAQs
Data Sources
Contact Us
Display Options:
Drug type
Therapeutic Area
Route of administration
Mechanism of Action
Indication
Status
Total:
6532
RABUSERTIB
2
Small molecule
Investigational
Unknown
Unknown
Neoplasms; Pancreatic Neoplasms; Carcinoma, Non-Small-Cell Lung
Serine/threonine-protein kinase Chk1 inhibitor
RABUSERTIB
×
Maximum Phase:
2
First Approval:
None
UNII:
3S9L1NU6U7
Molecule Type:
Small molecule
Molecular Formula:
C18H22BrN5O3
Molecular Weight:
436.31
AlogP:
2.87
PSA:
97.4
HBD:
3.0
HBA:
#RotB:
5.0
Source:
ORGANON
2
Small molecule
Investigational
Unknown
Unknown
Substance-Related Disorders
Unknown
ORGANON
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Small molecule
Molecular Formula:
C26H35N3O3
Molecular Weight:
437.58
AlogP:
4.78
PSA:
59.49
HBD:
1.0
HBA:
#RotB:
8.0
Source:
BERSACAPAVIR
2
Small molecule
Investigational
Unknown
Unknown
Hepatitis; Liver Diseases; Renal Insufficiency; Hepatitis B, Chronic
Unknown
BERSACAPAVIR
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Small molecule
Molecular Formula:
C16H14F4N4O3S
Molecular Weight:
418.37
AlogP:
2.52
PSA:
103.99
HBD:
2.0
HBA:
#RotB:
5.0
Source:
GOVORESTAT
2
Small molecule
Investigational
Unknown
Unknown
Galactosemias
Unknown
GOVORESTAT
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Small molecule
Molecular Formula:
C17H10F3N3O3S2
Molecular Weight:
425.41
AlogP:
3.76
PSA:
85.08
HBD:
1.0
HBA:
#RotB:
4.0
Source:
BRILACIDIN
2
Small molecule
Investigational
Unknown
Unknown
Severe Acute Respiratory Syndrome
Membrane disrupting agent
BRILACIDIN
×
Maximum Phase:
2
First Approval:
None
UNII:
I1679X069H
Molecule Type:
Small molecule
Molecular Formula:
C40H50F6N14O6
Molecular Weight:
936.92
AlogP:
3.68
PSA:
308.5
HBD:
12.0
HBA:
#RotB:
20.0
Source:
GLPG-1205
2
Small molecule
Investigational
Unknown
Unknown
Colitis, Ulcerative; Idiopathic Pulmonary Fibrosis
G-protein coupled receptor 84 negative allosteric modulator
GLPG-1205
×
Maximum Phase:
2
First Approval:
None
UNII:
K9WR6LRA5D
Molecule Type:
Small molecule
Molecular Formula:
C22H22N2O4
Molecular Weight:
378.43
AlogP:
2.02
PSA:
62.58
HBD:
0.0
HBA:
#RotB:
3.0
Source:
LOTAMILAST
2
Small molecule
Investigational
Unknown
Unknown
Dermatitis, Atopic
Phosphodiesterase 4 inhibitor
LOTAMILAST
×
Maximum Phase:
2
First Approval:
None
UNII:
TO043KKB9C
Molecule Type:
Small molecule
Molecular Formula:
C26H24N4O5
Molecular Weight:
472.5
AlogP:
4.39
PSA:
111.67
HBD:
2.0
HBA:
#RotB:
7.0
Source:
IFETROBAN
2
Small molecule
Investigational
Unknown
Unknown
Asthma; Muscular Dystrophy, Duchenne; Renal Insufficiency; Respiratory Tract Diseases
Unknown
IFETROBAN
×
Maximum Phase:
2
First Approval:
None
UNII:
E833KT807K
Molecule Type:
Small molecule
Molecular Formula:
C25H32N2O5
Molecular Weight:
440.54
AlogP:
4.12
PSA:
101.66
HBD:
2.0
HBA:
#RotB:
11.0
Source:
AGANEPAG ISOPROPYL
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Unknown
AGANEPAG ISOPROPYL
×
Maximum Phase:
2
First Approval:
None
UNII:
R096XE6760
Molecule Type:
Small molecule
Molecular Formula:
C27H37NO4S
Molecular Weight:
471.66
AlogP:
6.45
PSA:
66.84
HBD:
1.0
HBA:
#RotB:
12.0
Source:
APLINDORE FUMARATE
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Dopamine D2 receptor partial agonist
APLINDORE FUMARATE
×
Maximum Phase:
2
First Approval:
None
UNII:
P13TV5A758
Molecule Type:
Small molecule
Molecular Formula:
C22H22N2O7
Molecular Weight:
426.43
AlogP:
2.11
PSA:
59.59
HBD:
2.0
HBA:
#RotB:
4.0
Source:
ST-101
2
Small molecule
Investigational
Unknown
Unknown
Neoplasms; Alzheimer Disease; Essential Tremor
Unknown
ST-101
×
Maximum Phase:
2
First Approval:
None
UNII:
7TTT61784C
Molecule Type:
Small molecule
Molecular Formula:
C15H12N2O
Molecular Weight:
236.27
AlogP:
1.85
PSA:
32.67
HBD:
0.0
HBA:
#RotB:
0.0
Source:
RELENOPRIDE
2
Small molecule
Investigational
Unknown
Unknown
Constipation
Unknown
RELENOPRIDE
×
Maximum Phase:
2
First Approval:
None
UNII:
SIS5BFO4WL
Molecule Type:
Small molecule
Molecular Formula:
C24H30ClFN4O4
Molecular Weight:
492.98
AlogP:
3.74
PSA:
119.91
HBD:
3.0
HBA:
#RotB:
9.0
Source:
AZD-9164
2
Small molecule
Investigational
Unknown
Unknown
Pulmonary Disease, Chronic Obstructive
Unknown
AZD-9164
×
Maximum Phase:
2
First Approval:
None
UNII:
977LWC4O5D
Molecule Type:
Small molecule
Molecular Formula:
C29H38FN2O2+
Molecular Weight:
465.63
AlogP:
4.92
PSA:
29.54
HBD:
0.0
HBA:
#RotB:
7.0
Source:
SJG-136
2
Small molecule
Investigational
Unknown
Unknown
Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid, Acute; Neoplasms
DNA cross-linking agent
SJG-136
×
Maximum Phase:
2
First Approval:
None
UNII:
KT0ZQ64X1A
Molecule Type:
Small molecule
Molecular Formula:
C31H32N4O6
Molecular Weight:
556.62
AlogP:
4.52
PSA:
102.26
HBD:
0.0
HBA:
#RotB:
8.0
Source:
SNX 5422
2
Small molecule
Investigational
Unknown
Unknown
Hematologic Neoplasms; Leukemia; Lymphoma; Neoplasms
Heat shock protein HSP90 inhibitor
SNX 5422
×
Maximum Phase:
2
First Approval:
None
UNII:
BF52J69Q8T
Molecule Type:
Small molecule
Molecular Formula:
C25H30F3N5O4
Molecular Weight:
521.54
AlogP:
3.37
PSA:
142.33
HBD:
3.0
HBA:
#RotB:
6.0
Source:
PETESICATIB
2
Small molecule
Investigational
Unknown
Unknown
Celiac Disease; Sjogren's Syndrome
Cathepsin S inhibitor
PETESICATIB
×
Maximum Phase:
2
First Approval:
None
UNII:
A26QO95U37
Molecule Type:
Small molecule
Molecular Formula:
C25H23F6N5O4S
Molecular Weight:
603.55
AlogP:
3.36
PSA:
125.16
HBD:
1.0
HBA:
#RotB:
6.0
Source:
ATAGABALIN
2
Small molecule
Investigational
Unknown
Unknown
Sleep Initiation and Maintenance Disorders
Voltage-gated calcium channel modulator
ATAGABALIN
×
Maximum Phase:
2
First Approval:
None
UNII:
JT7957Q2FB
Molecule Type:
Small molecule
Molecular Formula:
C10H19NO2
Molecular Weight:
185.27
AlogP:
1.47
PSA:
63.32
HBD:
2.0
HBA:
#RotB:
3.0
Source:
NESOLICAFTOR
2
Small molecule
Investigational
Unknown
Unknown
Cystic Fibrosis
Unknown
NESOLICAFTOR
×
Maximum Phase:
2
First Approval:
None
UNII:
T2U4ZA62U4
Molecule Type:
Small molecule
Molecular Formula:
C18H18N4O4
Molecular Weight:
354.37
AlogP:
2.45
PSA:
114.28
HBD:
2.0
HBA:
#RotB:
5.0
Source:
ELLAGIC ACID
2
Small molecule
Investigational
Unknown
Unknown
Lymphoma, Follicular
Unknown
ELLAGIC ACID
×
Maximum Phase:
2
First Approval:
None
UNII:
19YRN3ZS9P
Molecule Type:
Small molecule
Molecular Formula:
C14H6O8
Molecular Weight:
302.19
AlogP:
1.31
PSA:
141.34
HBD:
4.0
HBA:
#RotB:
0.0
Source:
ZONAMPANEL
2
Small molecule
Investigational
Unknown
Unknown
Ischemic Stroke; Stroke
Glutamate receptor ionotropic AMPA antagonist
ZONAMPANEL
×
Maximum Phase:
2
First Approval:
None
UNII:
9X33544ILS
Molecule Type:
Small molecule
Molecular Formula:
C13H9N5O6
Molecular Weight:
331.24
AlogP:
-0.13
PSA:
153.12
HBD:
2.0
HBA:
#RotB:
4.0
Source:
AZD7986
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Unknown
AZD7986
×
Maximum Phase:
2
First Approval:
None
UNII:
Molecule Type:
Small molecule
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
BMS-986141
2
Small molecule
Investigational
Unknown
Unknown
Ischemic Stroke; Liver Diseases; Thrombosis
Proteinase activated receptor 4 antagonist
BMS-986141
×
Maximum Phase:
2
First Approval:
None
UNII:
W530IRZ40G
Molecule Type:
Small molecule
Molecular Formula:
C27H23N5O5S2
Molecular Weight:
561.65
AlogP:
5.63
PSA:
104.22
HBD:
0.0
HBA:
#RotB:
8.0
Source:
TOCOTRIENOL
2
Small molecule
Investigational
Unknown
Unknown
Breast Neoplasms; Colorectal Neoplasms; Ovarian Neoplasms; Ischemic Stroke
Unknown
TOCOTRIENOL
×
Maximum Phase:
2
First Approval:
None
UNII:
0867I0N41V
Molecule Type:
Small molecule
Molecular Formula:
C26H38O2
Molecular Weight:
382.59
AlogP:
7.68
PSA:
29.46
HBD:
1.0
HBA:
#RotB:
9.0
Source:
BMS-690514
2
Small molecule
Investigational
Unknown
Unknown
Neoplasms; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung
Epidermal growth factor receptor erbB1 inhibitor
BMS-690514
×
Maximum Phase:
2
First Approval:
None
UNII:
VKU5X213Q7
Molecule Type:
Small molecule
Molecular Formula:
C19H24N6O2
Molecular Weight:
368.44
AlogP:
1.38
PSA:
100.94
HBD:
3.0
HBA:
#RotB:
5.0
Source:
LY2801653
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Unknown
LY2801653
×
Maximum Phase:
2
First Approval:
None
UNII:
Molecule Type:
Small molecule
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
SEPANTRONIUM
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Unknown
SEPANTRONIUM
×
Maximum Phase:
2
First Approval:
None
UNII:
UZ77T1VFBM
Molecule Type:
Small molecule
Molecular Formula:
C20H19N4O3+
Molecular Weight:
363.4
AlogP:
1.34
PSA:
77.96
HBD:
0.0
HBA:
#RotB:
5.0
Source:
OLVEREMBATINIB
2
Small molecule
Investigational
Unknown
Unknown
Gastrointestinal Stromal Tumors; Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Bcr/Abl fusion protein inhibitor
OLVEREMBATINIB
×
Maximum Phase:
2
First Approval:
None
UNII:
KV1M7Q3CBP
Molecule Type:
Small molecule
Molecular Formula:
C29H27F3N6O
Molecular Weight:
532.57
AlogP:
4.68
PSA:
77.15
HBD:
2.0
HBA:
#RotB:
4.0
Source:
EDICOTINIB
2
Small molecule
Investigational
Unknown
Unknown
Prostatic Neoplasms; Arthritis, Rheumatoid; Leukemia, Myeloid, Acute
Macrophage colony stimulating factor receptor inhibitor
EDICOTINIB
×
Maximum Phase:
2
First Approval:
None
UNII:
3NU609VYNF
Molecule Type:
Small molecule
Molecular Formula:
C27H35N5O2
Molecular Weight:
461.61
AlogP:
5.97
PSA:
103.69
HBD:
2.0
HBA:
#RotB:
4.0
Source:
SODIUM ACID PYROPHOSPHATE
2
Small molecule
Investigational
Unknown
Unknown
Pseudoxanthoma Elasticum
Unknown
SODIUM ACID PYROPHOSPHATE
×
Maximum Phase:
2
First Approval:
None
UNII:
H5WVD9LZUD
Molecule Type:
Small molecule
Molecular Formula:
H2Na2O7P2
Molecular Weight:
221.94
AlogP:
-0.81
PSA:
124.29
HBD:
4.0
HBA:
#RotB:
2.0
Source:
CH-1504 L-ISOMER
2
Small molecule
Investigational
Unknown
Unknown
Arthritis, Rheumatoid
Unknown
CH-1504 L-ISOMER
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Small molecule
Molecular Formula:
C23H23N5O5
Molecular Weight:
449.47
AlogP:
1.79
PSA:
181.52
HBD:
5.0
HBA:
#RotB:
9.0
Source:
SR16234
2
Small molecule
Investigational
Unknown
Unknown
Breast Neoplasms
Estrogen receptor alpha antagonist
SR16234
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Small molecule
Molecular Formula:
C33H47NO3
Molecular Weight:
505.74
AlogP:
7.43
PSA:
41.93
HBD:
1.0
HBA:
#RotB:
9.0
Source:
ORILOTIMOD POTASSIUM
2
Small molecule
Investigational
Unknown
Unknown
Psoriasis
Unknown
ORILOTIMOD POTASSIUM
×
Maximum Phase:
2
First Approval:
None
UNII:
Q8858ZSK4Y
Molecule Type:
Small molecule
Molecular Formula:
C16H18KN3O5
Molecular Weight:
371.43
AlogP:
0.47
PSA:
145.51
HBD:
5.0
HBA:
#RotB:
8.0
Source:
MOLIBRESIB
2
Small molecule
Investigational
Unknown
Unknown
Carcinoma; Neoplasms
Bromodomain and extra-terminal motif (BET) inhibitor
MOLIBRESIB
×
Maximum Phase:
2
First Approval:
None
UNII:
5QIO6SRZ2R
Molecule Type:
Small molecule
Molecular Formula:
C22H22ClN5O2
Molecular Weight:
423.9
AlogP:
3.66
PSA:
81.4
HBD:
1.0
HBA:
#RotB:
5.0
Source:
GANDOTINIB
2
Small molecule
Investigational
Unknown
Unknown
Neoplasms
Tyrosine-protein kinase JAK2 inhibitor
GANDOTINIB
×
Maximum Phase:
2
First Approval:
None
UNII:
ANC71R916O
Molecule Type:
Small molecule
Molecular Formula:
C23H25ClFN7O
Molecular Weight:
469.95
AlogP:
4.03
PSA:
83.37
HBD:
2.0
HBA:
#RotB:
6.0
Source:
DONITRIPTAN
2
Small molecule
Investigational
Unknown
Unknown
Unknown
G protein-coupled receptor 44 antagonist
DONITRIPTAN
×
Maximum Phase:
2
First Approval:
None
UNII:
70968BVH2J
Molecule Type:
Small molecule
Molecular Formula:
C23H25N5O2
Molecular Weight:
403.49
AlogP:
2.27
PSA:
98.38
HBD:
2.0
HBA:
#RotB:
6.0
Source:
1
2
…
107
108
109
110
111
112
113
…
186
187
Next »
Download Option
Close
Header
Compound Name
Maximum Phase
Compound Structure
Smile
Inchi
InchiKey
Compound Properties
Molecular Formula
Molecular Weight
ALogP
PSA